Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
分析日: 2026-05-08次回更新: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
株価
$378.06
▼ -38.07 (-10.07%)
公正価値
$340
$340–$450
評価
縮小
confidence 88/100
上昇余地
-10.1%
upside to fair value
安全余裕率
$288.99
buy below · 15%
時価総額
$343.3B
P/E fwd 18.2
英語版にフォールバックJA
翻訳中のため英語版を表示しています
このレポートはまだ翻訳されていません。翻訳キューが追いついたら数分後に更新してください。

§1 エグゼクティブサマリー

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 ベアケース

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

このテーゼが崩れる経路

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
監視すべき早期警戒シグナル
指標現在トリガーしきい値
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 財務履歴

損益計算書 — 直近6期
項目T−0T−1T−2T−3T−4CAGR
期間2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
売上高$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
売上総利益$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
営業利益$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
純利益$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
EPS (希薄化後)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
研究開発
販管費

品質スコア

Piotroski F-スコア
6 / 9
0–9 品質コンポジット
Altman Zスコア
2.97
倒産リスク (>3 で安全)
OCF / 純利益
1.63×
>1 は利益の質が高いことを示す
会計品質ゲート
Pass
セクター調整後ゲート
ROIC
8.6%
投下資本利益率
セクション 3

Numbers analysis

資本配分

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

個人サブスクライバー — §4以降11セクション追加

完全な分析を読む — 11セクション追加。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

カバー対象の全ティッカーの完全なレポート
24か月分の評価アーカイブ
ウォッチリストブリーフィング + 評価変更アラート
任意の言語でのPDF + DOCXエクスポート
無料トライアルを開始
いつでもキャンセル可能。
FAQ

UNH — frequently asked questions

  1. Based on our latest analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care